Germline JAK2 mutation in a family with hereditary thrombocytosis

New England Journal of Medicine

Volumn 366, Issue 10, 2012, Pages 967-969

  Mead, Adam J ^a   Rugless, Michelle J ^b   Jacobsen, Sten Eirik W ^a   Schuh, Anna ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

STAT3 PROTEIN; THROMBOPOIETIN;

AUTOSOMAL DOMINANT INHERITANCE; BONE MARROW CANCER; BONE MARROW EXAMINATION; FAMILY HISTORY; GENE; GENE FUNCTION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SCREENING; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; HUMAN; JAK2 GENE; LETTER; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; PEDIGREE ANALYSIS; PHENOTYPIC VARIATION; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; THROMBOCYTE COUNT; THROMBOCYTOSIS;

EID: 84857863366     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1200349     Document Type: Letter

References (5)

1. Cross NC. Genetic and epigenetic complexity in myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2011;2011:208-14.
2. Dusa A, Staerk J, Elliott J, et al. Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J Biol Chem 2008;283:12941-8.
3. Lee TS, Ma W, Zhang X, Kantarjian H, Albitar M. Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations. BMC Struct Biol 2009;9:58.
4. Ma W, Kantarjian H, Zhang X, et al. Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias. J Mol Diagn 2009;11:49-53.
5. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61. [Erratum, Lancet 2005;366:122.] (Pubitemid 40386783)